Jinwon Life Sciences Subsidiary Strengthens Collaboration with US Genius Therapeutics on Personalized Cancer Treatments

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 17th that its subsidiary VGXI, a cGMP contract development and manufacturing organization (CDMO) specializing in excellent pharmaceutical manufacturing, has signed an additional supply agreement for the 1b/2a clinical trial with the U.S. company Geneos Therapeutics, which is developing a treatment for advanced hepatocellular carcinoma (HCC).

Geneos Therapeutics' therapeutic candidate (GT-30) clinical trial focuses on treating patients with advanced hepatocellular carcinoma, an aggressive form of liver cancer, using the GT-EPIC platform, a cancer antigen-targeted personalized immunotherapy platform.

VGXI has completed the development of a rapid production process capable of producing clinical-grade plasmid DNA without quality differences even with reduced standard production operation time for the GT-30 clinical trial. They also successfully supplied clinical-grade drugs during the early clinical stages of GT-30, demonstrating suitability for producing personalized therapies requiring rapid manufacturing.

Park Young-geun, CEO of GeneOne Life Science, said, “We are grateful to strengthen cooperation with Geneos Therapeutics and sign an additional supply agreement,” adding, “The signing of this additional supply agreement is evidence of VGXI’s experience and capability to meet the stringent requirements related to the production of this product.”

He continued, “We hope that Geneos Therapeutics’ clinical trial will successfully advance to the next stage and that VGXI can support this progress.”

Dr. Niranjan Y. Sardesai, founder and CEO of Geneos Therapeutics, said, “We are pleased to further strengthen our collaboration with VGXI during the development of GT-30, a sophisticated personalized immunotherapy for treating patients,” adding, “VGXI, with its innovative technology, has enabled us to shorten the time from analyzing patients’ tumor tissues to administering personalized therapies based on GT-EPIC, which has become one of Geneos Therapeutics’ key differentiating technologies.”

Personalized cancer therapies use cancer antigens derived from individuals, making them more effective and less prone to side effects than conventional immune checkpoint inhibitors, attracting attention from multinational pharmaceutical companies.

This content was produced with the assistance of AI translation services.